(Reuters) – Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with no serious side effects or infusion-related adverse events in the 48-patient, 12-week Phase II study, the company said. Among patients previously treated with at least one biologic drug, the common measure of 20 percent relief of signs and symptoms of the arthritis, known as ACR20, was achieved by 55 percent of those who received an infusion of 2 million cells per kilogram of weight.
Original post:
Mesoblast cell treatment shows promise in rheumatoid arthritis -study
